Appendix Table 3.
Association Between LDL Subfraction and Incident Cardiovascular Events (Not Full Extraction)
Author, Year (Reference) |
Type of Test |
Study Design | Mean Age, y* |
Persons >65 y, %† |
Men, %* | Diabetic Persons, %* |
Smokers, % | Lipid Data |
---|---|---|---|---|---|---|---|---|
Howard et al, 2000 (36) | No data | Prospective longitudinal | 56 | ~15 | Not reported | 47 | 35 (current) | LDL-c: 113 mg/dL |
Arsenault et al, 2007 (23) | GE | Nested case–control | 65 | ~50 | 64 | 6 | 16 (current) | LDL-c: 162 mg/dL |
St-Pierre et al, 2005 (29) | GE | Prospective longitudinal | 57 | 0 | 100 | 5 | 23 (current) | LDL-c: 148 mg/dL |
Stampfer et al, 1996 (30) | GE | Nested case–control | 59 | ~25 | 100 | 6 | 56 (ever smoked) | TC–HDL-c ratio: 5.2 |
Campos et al, 2001 (25) | GE | Nested case–control | 60 | ~30 | 87 | 16 | 17 (current) | LDL-c: 139 mg/dL |
Austin et al, 2000 (24) | GE | Nested case–control | 68 | ~70 | 100 | 17 | 63 (ever smoked) | LDL-c: 142 mg/dL |
Mykkänen et al, 1999 (27) | GE | Nested case–control | 69 | 100 | 50 | 33 | 20 (current) | TC–HDL-c ratio: 6.09 |
Gardner et al, 1996 (26) | GE | Nested case–control | 59 | 33 | 73 | No data | 42 (not defined) | Non–HDL-c: 176 mg/dL |
LDL Subfraction Data | Sample | Duration of Follow-up, y |
Outcome | Predictor† | Results§ |
|
---|---|---|---|---|---|---|
Unadjusted | Adjusted | |||||
Mean size, 259.1 Å | 3668 or 4378 American Indians | Mean, 4.8 | Fatal and nonfatal CVD event | |||
Women | Size | + | ||||
Men | Size | 0 | ||||
Diabetic persons | Size | |||||
Mean size, 260 Å; <255 Å, 29% | Men: 660 with CAD event, 1209 control participants | Mean, 7.7 | Fatal or nonfatal CHD Men | |||
Men | Size | + | ||||
Pattern | + | + | ||||
Women: 375 with CAD event, 777 control participants | Women | Size | + | |||
Pattern | + | + | ||||
Mean size, 256.9 Å; pattern B, 40% | 2072 healthy persons | Unadjusted, 13; adjusted, 5¶ | Ischemic CAD event | Size Pattern |
0 + |
+ |
Mean size, 256 Å; pattern B, 47%; indeterminate pattern, 20% | 266 with CAD event, 308 control participants | 7 | Incident MI or CAD death | Size Pattern |
+ + |
0 0 |
Mean size, 256 Å | Unadjusted analysis: 416 with CAD
event, 421 control participants Adjusted analysis: 242 with CAD event, 218 control participants |
Median, 5 | Confirmed MI or CAD death (on placebo) | Size | + | + |
Mean size, 260.0 Å | 145 with incident CHD, 296 control participants | 12 | Incident CAD: MI or coronary intervention | Size Pattern |
+ + |
0 |
Mean size, 268.2 Å; pattern B or indeterminate pattern, 21% | 86 with CAD event, 172 control participants | Mean, 3.5 | Incident MI or CAD death | Size Pattern |
0 0 |
0 |
Mean size, 261.7 Å; <260 Å, 40%; >274.2 Å, 10% | 124 with CAD event, 124 with no event | Mean, 5 to CAD event | Incident MI or CAD death | Size Pattern+ |
+ +** |
+ |
CAD coronary artery disease; CHD coronary heart disease; GE gel electrophoresis; HDL-c high-density lipoprotein cholesterol; LDL-c low-density lipoprotein cholesterol; MI myocardial infarction; TC total cholesterol.
Of case patients in case–control or cross-sectional studies (when reported separately); data at baseline.
Approximate data were estimated from means (SDs) rounded to the nearest 5%; otherwise, data are the reported values.
“Size” refers to analysis based on actual particle size (regression or comparisons of mean sizes); “pattern” refers to analysis based on distribution across categories of LDL subfractions (small, medium, or large).
+ smaller particles were statistically significantly associated with worse cardiovascular outcomes; 0 no statistically significant association between LDL subfractions and cardiovascular outcomes.
It was unclear how many participants were analyzed.
From reference 44.
The authors reported an association between LDL subfraction and cardiovascular outcomes, but no statistical analysis was performed.